Clinical trials
Pharmacodynamics clinical trials
Below are recruiting pharmacodynamics clinical trials, each written for real people, not researchers. We’re tracking 160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05806099RecruitingPhase 1/Phase 2
Study of MBS303 for CD20-positive B-cell lymphoma that returned
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
BeijingAges 18 years+ - NCT07626281RecruitingPhase 1
Safety study of new inclisiran formulation for cholesterol
This trial tests a new version of inclisiran, a cholesterol-lowering medicine, to see if it is safe and works well. The study compares it to the current version. You may qualify if you have moderately high cholesterol but have never taken cholesterol medications.
Lenexa, KansasAges 18–60 - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT07619885RecruitingPhase 1
Testing a New Blood Thinner Called CG-0255 in Healthy People
This study tests how a new blood-thinning medication (CG-0255) works in the body and compares it with Plavix, a common blood thinner. Researchers will measure how much of the drug enters your bloodstream and what effects it has on your blood clotting ability.
Miami, FloridaAges 18–55 - NCT07610278RecruitingPhase 2
Blood Pressure and Cholesterol Treatment Study
This study tests a combination of two new medications (QCZ484 and inclisiran) designed to lower both blood pressure and cholesterol levels. You may be a good fit if you have high blood pressure and high cholesterol that isn't fully controlled by current treatments.
Foley, AlabamaAges 18–75 - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT07600476RecruitingPhase 1
Safety Study of KUP-101A in Advanced Solid Tumors
This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.
Munich, BavariaAges 18 years+ - NCT06718517Recruiting
Testing drug levels to improve antibiotic therapy in liver transplant patients
This trial checks if monitoring antibiotic levels in the blood can help doctors give the right dose to liver transplant patients with serious bacterial infections. The goal is to make the treatment work better.
BolognaAges 18 years+ - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07581431RecruitingPhase 1
Testing ISM8969 in healthy and obese adults with heart disease risk
This early-stage trial tests a new drug called ISM8969 to see if it's safe and how the body handles it. Participants are either healthy adults or adults who are overweight with risk factors for heart disease, like high blood pressure or high cholesterol.
Melbourne, VictoriaAges 18–80 - NCT07577817RecruitingEarly Phase 1
Safety Study of CTX001 in Healthy Adults
This early-stage study tests a new experimental drug called CTX001 in healthy volunteers to check if it is safe and well-tolerated. Researchers will also measure how your body processes the drug and how it affects certain blood markers.
Melbourne, VictoriaAges 18–55 - NCT07577206RecruitingEarly Phase 1
New PET Scan Tracer for Advanced Solid Cancers
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Naples, ItaliaAges 18 years+ - NCT07567872RecruitingPhase 1
Inhaled HRS-9821 Safety Study in Healthy People and COPD Patients
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
Chengdu, SichuanAges 18–75 - NCT06715540RecruitingPhase 1
Study of a new drug for healthy male volunteers
This trial tests a new medicine called BCD-261 in healthy men to see if it is safe and how the body processes it. Participants will receive increasing doses and be monitored for about 4 months.
Saint PetersburgAges 18–45 - NCT07557420RecruitingPhase 3
Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
BeijingAges 18–130 - NCT06635226RecruitingPhase 1
Safety study of ID110521156 in healthy adults
This study tests a new investigational drug called ID110521156 in healthy adults. The goal is to see if the drug is safe and how the body processes it. It may be for people who are overweight or obese.
SeoulAges 19–50 - NCT07540910RecruitingPhase 1
Safety study of EDP-978 in healthy adults
This is an early-stage study testing a new experimental drug called EDP-978 in healthy volunteers to see if it is safe and how the body processes it. Researchers will give participants single or multiple doses and monitor for side effects and how the drug moves through the body.
San Antonio, TexasAges 18–65 - NCT07536269RecruitingPhase 2
Safety study of crinecerfont for very young children with CAH
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
San Francisco, CaliforniaAges 3 months–3.9 years - NCT07535099RecruitingPhase 1
Safety study of ICP-538 in healthy volunteers
This trial tests a new drug called ICP-538 in healthy people to see how safe it is and how the body processes it. It is an early-phase study that helps decide if the drug can move to testing in patients with a specific condition.
Beijing, Beijing MunicipalityAges 18–50 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07511205RecruitingPhase 1
Study of AZD1043 for overweight or obesity
This trial tests a new medicine called AZD1043 in healthy adults who are overweight or have obesity. It aims to see if the medicine is safe and how the body handles it.
Glendale, CaliforniaAges 18–65 - NCT07514780RecruitingPhase 1
Safety study of JW0061 in healthy adults
This is an early-stage safety test of a new drug called JW0061 in people without serious health conditions. Researchers will monitor how your body processes the drug and any side effects that occur.
Seoul, SeoulAges 19–55 - NCT07505030Enrolling by invitationPhase 1
Safety study of LYNC-101 in healthy adults
This trial tests a new medicine called LYNC-101 in healthy volunteers to see if it is safe and how the body processes it. If you are a generally healthy adult between 18 and 60, you may be able to help researchers learn about this potential treatment.
Adelaide, South AustraliaAges 3 weeks–2 months - NCT06556394RecruitingPhase 1
Testing RAG-17 for ALS with SOD1 gene mutation
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
BeijingAges 18 years+
Hear when a new Pharmacodynamics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pharmacodynamics?
- Yes. Clin2 currently lists 160 recruiting pharmacodynamics studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pharmacodynamics trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pharmacodynamics trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.